Aryeh Jason 4
4 · LIGAND PHARMACEUTICALS INC · Filed Jun 10, 2025
Insider Transaction Report
Form 4
Aryeh Jason
Director
Transactions
- Award
Common Stock
2025-06-06+1,209→ 79,289 total - Award
Non-Qualified Stock Option (right to buy)
2025-06-06+5,783→ 5,783 totalExercise: $105.99Exp: 2035-06-06→ Common Stock (5,783 underlying)
Holdings
- 5,025(indirect: By Trust)
Common Stock
- 51,594(indirect: Indirect)
Common Stock
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- [F2]All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
- [F3]Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.